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Background: Carotid artery stenting is an increasingly common endovascular treatment of carotid artery stenosis
advocated in high-risk patients despite reports of increased adverse periprocedural outcomes in patients aged >80 years.
We sought to evaluate our single institution experience with octogenarians and whether they have an increased incidence
of major complications with carotid artery stenting.
Methods: Three hundred eighty-six patients, including 260 patients from 10 regulatory trials, who underwent carotid
artery stenting between June 1996 and March 2004 for symptomatic or asymptomatic carotid stenosis were reviewed
from a prospectively maintained database. Periprocedural (<30 days after carotid artery stenting) cerebrovascular
accident, transient ischemic attack, myocardial infarction, and death outcomes were compared between 87 octogenarians
and 295 nonoctogenarians. Univariate and multivariate analysis was performed for confounding factors. Kaplan-Meier
analysis of stroke and death outcomes was performed for a 1-year follow-up.
Results: All adverse outcomes were significantly higher in octogenarians compared with younger patients: 30-day stroke
rate, 8.0% vs 2.7% (P .02); 30-day stroke, myocardial infarction, or death, 9.2% vs 3.4% (P .02). Cohorts were similar
in terms of gender, comorbidities, antiplatelet medications, symptomatic status, and use of cerebral protection.
Octogenarians had a greater incidence of contralateral internal carotid artery occlusion (26% vs 12%, P  .001), atrial
fibrillation (21% vs 8%, P  .001), and congestive heart failure (28% vs 15%, P  .007), but a lower incidence of
hypercholesterolemia (53% vs 72%, P  .001) and active smoking (8% vs 24%, P  .001). Multivariate analysis of 30-day
major adverse outcomes demonstrated an association between age>80 and adverse outcome (odds ratio, 2.85; P .043)
as well as a protective effect of the preprocedural use of aspirin (odds ratio, 0.30, P .027). At 1-year follow-up, only 75%
of octogenarians and 87% of nonoctogenarians were free from stroke, myocardial infarction, or death (P  005,
Kaplan-Meier analysis).
Conclusions: Octogenarians undergoing carotid artery stenting are at higher risk than nonoctogenarians for periproce-
dural complications, including neurologic events and death. Major event-free survival at 1 year is also significantly better
in nonoctogenarians. These risks should be weighed when considering carotid stenting in elderly patients. ( J Vasc Surg
2006;43:297-304.)Prospective, randomized trials have demonstrated stroke
prevention benefit to carotid endarterectomy plus medical
therapy vs medical therapy alone in the management of
patients with carotid artery stenosis.1,2 Specific exclusion
criteria limited entry into two major clinical trials, North
American Symptomatic Carotid Endarterectomy Trial
(NASCET) and Asymptomatic Carotid Atherosclerosis
Study (ACAS), to patients aged 80 years because of the
putative high risk of endarterectomy in octogenarians. Sev-
eral nonrandomized studies have since demonstrated the
comparable safety of carotid endarterectomy in octogenar-
ians.3-10 To date, the efficacy of carotid endarterectomy in
octogenarians has not been addressed in a randomized trial.
Carotid artery stenting, an increasingly common endo-
vascular procedure, shows promise as an alternative therapy
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carotid artery stenting in octogenarians is similarly contro-
versial. In an early carotid artery stenting series, octogenar-
ians had a greater incidence of periprocedural stroke (16%)
than did younger patients (5.4%). The authors concluded
that the greatest risk factor for 30-day stroke was age 80
years.12 Advancements such as cerebral protection devices
and flexible, crush-resistant nitinol stents were not available
at the time of this study. More recent trials of high-risk
patients that included up to 20% octogenarians show good
clinical results supporting that carotid artery stenting is not
inferior to carotid endarterectomy.18
In the past year, Hobson et al19 published periproce-
dural results of 749 patients from the lead-in phase of the
Carotid Revascularization Endarterectomy versus Stent
Trial (CREST). Octogenarians had a markedly elevated
30-day periprocedural stroke rate of 12.1% vs 4.0% in
nonoctogenarians. The rate for stroke or death was also
higher for older patients (12.1% vs 4.4%). This significant
difference was not mediated by symptomatic status, ana-
tomic factors, protective devices, or degree of stenosis.19 As
a result of these findings, octogenarians have been excluded
from further enrollment in the CREST trial, which used a
single stent and protection device system.
Our goal in this study was to evaluate our prospectively
maintained database of carotid stent patients to determine
297
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METHODS
This study was approved by the Institutional Review
Board of the University of Pittsburgh.
Definitions. Stroke or cerebrovascular accident (CVA)
was defined as a neurologic deficit lasting at least 24 hours.
No distinction was made between minor strokes and major
strokes, and all strokes were included. Transient ischemic
attack (TIA) was defined as focal retinal or cerebral event
from which there was no neurologic sequelae after 24
hours. Death was qualified as either a direct sequelae of
stroke or due to another etiology.
Patients. From June 1996 to March 2004, 386 pa-
tients were scheduled for internal carotid artery stenting.
Neurologists evaluated the patients before the carotid
stenting procedures. Patients were considered symptomatic
if they had TIAs, amaurosis fugax, or strokes with clinically-
correlated, lateralizing symptoms 60 days preceding the
carotid intervention. Outside of this window, patients were
considered to be asymptomatic.
Carotid artery stent procedure. Patients underwent
carotid stenting in the angiography suite by one of three
interventionalists. Procedures were performed under local
anesthesia with intravenous sedation. Cerebral angiogra-
phy was performed before the procedure, and the percent
stenosis was determined by the NASCET method.1 Symp-
tomatic patients underwent stenting for 50% stenosis,
and asymptomatic patients underwent stenting for 80%
stenosis.
During the first year of patient accrual, patients were
treated preprocedurally with ticlopidine (250 mg twice
a day). In the ensuing years of the study, patients received a
preprocedural 300-mg loading dose of clopidogrel and a
maintenance, postprocedural dose of 75 mg/day for 3
months. Aspirin was initiated only if indicated by the reg-
ulatory trial in which the patient was enrolled; otherwise,
preprocedural aspirin was prescribed at the discretion of the
interventionalist. No changes were made to a patient’s
regimen if he or she were already taking aspirin. During
stenting, patients received anticoagulation with heparin to
a goal activated clotting time of 275 seconds.
The stent systems were inserted according to the regu-
latory trial protocol in which the patients were enrolled,
including Precise (Cordis Endovascular, Miami Lakes,
Fla), Smart (Cordis Endovascular), NextStent (EndoTex
Interventional Systems, Cupertino, Calif), Acculink
(Greenville, NC), Wallstent (Boston Scientific, Natick,
Mass), and EndoTex (Cupertino, Calif) stents. Embolic pro-
tection devices were also used according to the regulatory
trial protocol and included Angioguard (Cordis Endovas-
cular), Accunet (Guidant, Indianapolis, Ind), PercuSurge
(Medtronic, Minneapolis, Minn), and Epi (Boston Scien-
tific) devices. Patients not participating in a trial had stents
and protection devices inserted at the discretion of the inter-
ventionalist. Patients who received balloon-expandable stents
were excluded from this study.Data collection. All patients were entered into a pro-
spective database, and 68% were entered into one of 10
different regulatory trials. Comorbidities and current med-
ications were recorded. All periprocedural events were re-
corded. Stroke scales were not uniformly applied for pa-
tients not involved in regulatory trials. Major adverse events
included stroke, myocardial infarction, and death. TIAs
were also recorded. Minor adverse events included groin
site complications, hypotension requiring postprocedural
vasopressors, and urinary retention. For the complete list-
ing, see Results section.
Statistical analysis. Statistical analysis between octo-
genarians and nonoctogenarians was performed by using
the 2 statistic. When 2 was not appropriate for less frequent
occurrences, Fisher’s exact test was performed. The Wil-
coxon rank sum test was used to compare mean time of
follow-up. The Cochran-Mantel-Haenszel trend test was
used to examine age groupings for significant trends. Any
value expressed as P  .05 was considered significant.
The association between octogenarian status and the
composite 30-day outcome of stroke, myocardial infarc-
tion, or death was examined by using logistic regression.
The multivariable model included factors associated with
outcomes on univariate analysis as well as clinically relevant
variables believed to be associated with the outcome based
on prior research.
RESULTS
Follow-up. Mean length of hospital stay ( standard
deviation) was similar between patients aged80 and80
years, 1.8 2.0 and 2.2 2.7 days, respectively (PNS).
Mean length of follow-up for all patients was 415 days.
Mean follow-up for patients80 years was 431 days (max-
imum, 1327 days), and for patients 80 years, it was 361
days (maximum, 1172 days) (P  .036).
Baseline characteristics. In four (1.0%) of the 386
patients, carotid stenting was aborted before stent insertion
owing to technical complexity; none of these four devel-
oped subsequent morbidity.
Carotid artery stents were inserted in 382 patients with
asymptomatic and symptomatic carotid stenosis. Patient
clinical characteristics are delineated in Table I. Octogenar-
ians were an average of 14 years older than nonoctogenar-
ians. Men comprised 60% of both cohorts. Comorbidities
were similar except for an increased incidence of atrial
fibrillation (21% vs 8%, P  .001) and congestive heart
failure (28% vs 15%, P  .007) in octogenarians and a
decreased incidence of hypercholesterolemia (53% vs 72%,
P  .001) and active smoking (8% vs 24%, P  .001) in
octogenarians.
Asymptomatic carotid artery stenosis was present in
74% of patients 80 years old, and 71% of patients 80
years were asymptomatic (P  NS). Contralateral internal
carotid artery occlusion was more common in octogenari-
ans (26% vs 12%, P  .001) but was not significantly
associated with outcome by univariate analysis (odds ratio
[OR], 0.32, P .28). Cerebral protection was used in 62%
of octogenarians and 52% of nonoctogenarians (P .093).
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July 2000, approximately the midpoint of patient accrual.
Medication histories before carotid stenting were
not significantly different between the two cohorts, includ-
ing use of the antiplatelet agents aspirin and clopidogrel
(Table II). Use of statin anticholesterol medications was
more prevalent in patients80 years old (58% vs 33%, P
.001), paralleling the greater incidence of hypercholester-
olemia in this cohort. Similar percentages of patients took
antiplatelet medications recorded at the last follow-up
(Table II).
Periprocedural neurologic events and mortality.
Octogenarians had more major adverse events30 days of
the stenting procedure than younger patients (Table III).
The incidence of stroke was 2.7% in patients80 years old
and 8.0% in those 80 (P  .024). Periprocedural death
mirrored this disparity: 1.0% for nonoctogenarians vs 5.7%
for octogenarians (P  .007). By grouping major adverse
Table I. Patient characteristics before carotid stenting
Nonoctogenarians
(n  295) (%)
Octogenarians
(n  87) (%) P
Age (years) 69  7.6 83  2.7
Male 59.7 59.8 .985
CAD/MI 64.7 65.5 .895
CABG 36.3 37.9 .778
Atrial fibrillation 8.1 20.7 .001
CHF 14.9 27.6 .007
Hypercholesterolemia 71.5 52.9 .001
Hypertension 81.4 80.5 .851
COPD 18.0 12.6 .243
Diabetes mellitus 34.2 25.3 .116
Smoking history 80.3 73.6 .174
Active smoking 23.7 8.0 .001
Baseline creatinine 1.2 mg/dL 1.3 mg/dL .225
History of TIA 39 38 .860
History of CVA 28 21 .205
Asymptomatic 74 71 .626
Contralateral occlusion 12 26 .001
Cerebral protection 52 62 .093
CAD, Coronary artery disease; MI, myocardial infarction; CHF, congestive
heart failure; COPD, chronic obstructive pulmonary disease; TIA, transient
ischemic attack; CVA, cerebrovascular accident.
Table II. Medications of carotid stent patients
Nonoctogenarians
(%)
Octogenarians
(%) P
Preprocedure (n  295) (n  87)
Aspirin 82.4 85.1 .558
Clopidogrel 80.3 85.1 .320
Anticholesterol 58.3 33.3 .001
Nitrates 23.1 16.1 .165
Calcium-channel
blockers 33.2 25.3 .161
-blockers 40.3 28.7 .05
At follow-up (n  159) (n  48)
Aspirin 79.6 83.3 .582
Clopidogrel 39.7 43.8 .622events (stroke, myocardial infarction, or death), the inci-dence was 3.4% vs 9.2% in patients 80 years old vs those
80 (P  .024).
No significant difference was noted in the overall 30-
day stroke rate between symptomatic (4.9 %) and asymp-
tomatic (3.2%) patients (P  .44). Incidence of TIA 30
days was also not significantly different between symptom-
atic (3.9%) and asymptomatic (3.9%) patients (P  .99).
There was a significant trend even below the 80-year-
old threshold toward increasing adverse periprocedural
events with advancing age. The incidence of stroke in
patients70, 70 to 80, and80 years old was 2.3%, 3.1%,
and 8.0%, respectively (P .04 for trend). The incidence of
stroke, myocardial infarction, or death in patients 70, 70
to 80, and 80 years old was 2.3%, 4.3%, and 9.2%,
respectively (P  .02, for trend).
In terms of timing of 30-day strokes among nonocto-
genarians, seven of the eight total strokes occurred 24
hours of carotid artery stenting. One patient had a stroke
on postprocedure day 23. In octogenarians, six of the seven
total strokes occurred24 hours of carotid artery stenting.
One patient had a stroke on postprocedure day 1.
In terms of timing of 30-day TIAs in nonoctogenar-
ians, 10 of the 11 TIAs occurred within the first 24 hours
postprocedure. The additional TIA occurred on postpro-
cedure day 1. In octogenarians, all four of the TIAs oc-
curred within the first 24 hours postprocedure.
There was no significant difference between cohorts in
any minor periprocedural complications. The most com-
mon minor adverse event was vasopressor requirement,
occurring in 14.9% of nonoctogenarians and 10.8% of
octogenarians (P .30); 2.3% and 5.7%, respectively, had a
vasopressor requirement that prolonged hospital stay (P 
.118). Other complications similar in both cohorts in-
cluded groin hematomas and infections, urinary retention,
gastrointestinal bleeding, epistaxis, and arrhythmias.
Late survival and freedom from adverse events.
One-year Kaplan-Meier curves are shown in the Fig. Com-
posite survival (Fig, A) is significantly lower at 1 year for
octogenarians (81% vs 93%; P  .003): 14 of 87 octoge-
narians died within the first postprocedural year. Freedom
from stroke or death is shown in Fig, B. Only 76% of
octogenarians had stroke-free survival by 1 year. Fig, C
demonstrates the five additional strokes in nonoctogenar-
Table III. Major adverse events 30 days of stent
procedure
Nonoctogenarians
(n  295) (%)
Octogenarians
(n  87) (%) P
CVA 2.7 8.0 .024
TIA 3.7 4.6 .714
MI 0.7 1.1 .661
Death 1.0 5.7 .007
CVA or MI or death 3.4 9.2 .024
TIA, Transient ischemic attack; CVA, cerebrovascular accident; MI, myo-
cardial infarction.ians 30 days but 1 year, producing an overall 95.5%
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octogenarians, producing an overall 88.7% freedom from
stroke. With myocardial infarction taken into account
(Fig, D), only 75% of octogenarians are free from major
adverse events at 1 year. This is a considerably worse 1-year
outcome than the 87% seen in nonoctogenarians (P 
.005). Importantly, only 59% of nonoctogenarians and 45%
of octogenarians were available for follow-up at 1 year. This
corresponds to 44% of patients overall lost to follow-up by
1 year.
Univariate and multivariable analyses. Univariate
analysis was used to investigate 26 demographic, clinical,
and procedural variables for association with 30-day major
adverse events (stroke, myocardial infarction, and death).
Only two had statistically significant association: octoge-
narian status and preprocedural aspirin use (see Table IV).
Octogenarian status was associated with increased peripro-
cedural events, with an OR of 2.89 (P  .03). Preproce-
dural use of aspirin had a protective effect against major
adverse events (OR, 0.23; P  .004). Interestingly, con-
gestive heart failure (OR, 2.44) had a near-significant asso-
Fig. Kaplan-Meier curves for 1-year freedom from a
Cumulative survival: 19% of octogenarians did not surviv
of nonoctogenarians have freedom from stroke or death
1 year after stenting. C, Freedom from stroke: 11.3% o
advantage in nonoctogenarians continues from the perip
major adverse events: 25% of octogenarians and 13% of n
by 1 year.ciation with adverse outcome (P  .086), and cerebralprotection (OR, 0.40) had a near-significant reduction of
risk (P  .077).
Multivariate analysis was performed to evaluate for a
confounding effect, including individual variables with the
greatest association to outcome in a model with octogenar-
ian status (Table V). The final multivariate model indicated
that octogenarian status (P  .043) was associated with
major adverse periprocedural events. Preprocedural use of
aspirin (P  .027) was protective of major adverse events.
The goodness of fit, P  .92, indicates that the model fits
the data reasonably well.
DISCUSSION
Our data indicate that carotid stenting in octogenarians
is associated with a high risk of adverse events, both at 30
days and 1 year, and should be cautiously considered.
The influence of advanced patient age on the safety and
efficacy of intervention for carotid artery stenosis is contro-
versial. Multiple randomized clinical trials have demon-
strated that carotid endarterectomy reduces long-term
stroke risk in patients with symptomatic and asymptomatic
e events in nonoctogenarians and octogenarians. A,
year after carotid stenting. B, Stroke-free survival: 10%
ear; 24% of octogenarians either have a stroke or die by
ogenarians had strokes by 1 year. The freedom stroke
dural period out to 1-year follow-up. D, Freedom from
togenarians had a stroke, myocardial infarction, or dieddvers
e to 1
at 1 y
f oct
roce
onoccarotid stenosis, but none have included patients80 years
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that age has a negative impact on outcome after carotid
endarterectomy,22,23 but many other reports maintain that
age has no effect on early short-term outcomes.3-10
Controversy regarding the effect of age on outcome
surrounds carotid artery stenting as well. Chastain et al,24 in
a carotid stenting series of 158 patients published in 1999,
reported a major adverse event rate of 25% in octogenarians
vs 8.2% in younger patients.24 This group also reported a
20.8% stroke rate in octogenarians compared with the 7.6%
stroke rate in younger patients. In 2001, Roubin et al12
reported that age 80 had a negative impact on 30-day
adverse outcome; patients 80 years old had a 16% stroke
rate compared with 5.4% in younger patients.
That advances in the technical aspects of the procedure
will reduce morbidity and mortality from early studies is
certain; however, the association of advanced age with
worse outcome seems to be a persistent trend. A notable
exception was the study by Shawl et al25 in 2000 that
described a 2.9% stroke rate in 170 high-risk patients who
underwent carotid stenting. Forty-two of these patients
were octogenarians, only one of which had a stroke. There
were no differences in stroke rates: 3.1% in nonoctogenar-
ians and 2.4% in octogenarians.25 In the recent CREST
Table IV. Univariate association among 30-day stroke,
myocardial infarction, and death and selected
demographic, procedural, and clinical factors using
logistic regression
Factors OR 95% CI P
Age 80 years 2.89 1.10-7.56 .03
Male 1.37 0.50-3.73 .54
Diabetes mellitus 1.36 0.51-3.60 .53
Insulin use 0.49 0.06-3.78 .49
Hypertension 0.59 0.20-1.70 .33
Prior MI 1.78 0.67-4.71 .25
Coronary artery disease 1.43 0.50-4.09 .51
Atrial fibrillation 1.01 0.22-4.57 .99
Congestive heart failure 2.44 0.88-6.74 .086
COPD 0.28 0.04-2.15 .22
Hypercholesterolemia 0.47 0.18-1.21 .12
Prior CABG 1.35 0.56-3.28 .51
Peripheral vascular disease 2.06 0.77-5.47 .15
Smoking History 2.13 0.48-9.48 .32
Active smoking 0.77 0.22-2.74 .69
Prior TIA 1.19 0.77-1.84 .42
Prior CVA 1.84 0.71-4.76 .21
Aspirin use 0.23 0.09-0.63 .004
Clopidogrel use 0.57 0.19-1.65 .30
Statin use 0.43 0.16-1.18 .10
Nitrate use 0.44 0.10-1.97 .28
-blocker use 0.62 0.22-1.78 .38
Calcium-channel blocker use 0.42 0.12-1.48 .18
Asymptomatic presentation 0.55 0.21-1.47 .24
Contralateral occlusion 0.32 0.04-2.48 .28
Cerebral protection 0.40 0.15-1.10 .077
OR,Odds ratio;CI,Confidence interval;MI,myocardial infarction;COPD,
chronic obstructive pulmonary disease; CABG, coronary artery bypass graft;
TIA, transient ischemic attack; CVA, cerebrovascular accident.lead-in publication in 2004, however, Hobson et al19 re-ported a 12% 30-day stroke rate and a 12% stroke and death
rate in octogenarians who underwent carotid stenting.
Nonoctogenarians had a 2.8% stroke rate and a 3.2% stroke
or death rate. This multicenter report was restricted to one
stent and cerebral protection system. Long-term outcomes
30 days were not provided.
In our report of 382 patients from a single institution
performed by three experienced interventionalists, results
are in line with national studies. Octogenarians had a sig-
nificantly increased periprocedural stroke rate (8.0%) and a
stroke or death rate (9.2%) comparable with the 12.1%
stroke and major adverse event rates in the CREST lead-in
phase.19 Nonoctogenarians, which included symptomatic
and asymptomatic patients, had a 2.7% stroke or death rate.
As a point of reference, the 30-day stroke and death rate in
ACAS was 1.5%,2 and NASCET was 5.0%.1
Of more interest is our data showing that octogenarian
status had a significant association with stroke and death
over a 1-year follow-up. Only 81% of stented octogenar-
ians from our study, 74% of whom are asymptomatic,
survived 1 year. One-year stroke-free survival was even
more worrisome at 76%, bringing into question the advis-
ability of treating asymptomatic patients 80 years old.
Clearly, no medically treated cohort data are available
to us for comparison. A randomized trial of carotid artery
stenting vs medical therapy in this subgroup of patients may
be appropriate to elucidate appropriate management strat-
egies. These results are not unique. Roubin et al12 noted
that 20% of octogenarians had fatal and nonfatal strokes by
the first year of a 3-year follow-up Kaplan-Meier analysis.12
Interestingly, preprocedural use of aspirin had a protec-
tive effect frommajor adverse outcomes, stroke, myocardial
infarction, and death after stenting (Table IV). To our
knowledge, this has not been previously shown.25 In our
multivariate analysis, aspirin use had an OR of 0.30 (P 
.027). In the ACAS and NASCET trials, aspirin was con-
sidered the best medical therapy by which to compare the
stroke prevention of carotid endarterectomy.1,2 Preproce-
dural use of clopidogrel did not have a statistical correlation
with major adverse events outcome. This was surprising,
given the considerable stroke-prevention benefit associated
with clopidogrel use.26,27 There were not enough patients
without either medication to analyze the effect of “any
anti-platelet therapy” use on adverse outcomes.
Table V. Association between octogenarian status and
stroke, myocardial infarction, and death, adjusting for
other variables
Factors OR 95% CI P
Age 80 years 2.85 1.03-7.83 .043
Aspirin use 0.30 0.10-0.87 .027
Congestive heart failure 2.09 0.72-6.10 .17
Embolic protection device use 0.49 0.16-1.46 .20
OR, Odds ratio; CI, confidence interval.Two baseline patient comorbidities warrant noting:
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gestive heart failure (CHF) than nonoctogenarians (27.6%
vs 14.9%, P  .007). CHF in octogenarians had a con-
founding effect on the association of age with outcome,
although not quite significant by univariate analysis (OR,
2.44; P .086) or by multivariate analysis (OR, 2.09; P
.17). Previously, in a survey of 1160 randomly selected
carotid endarterectomies at 12 centers, CHF was shown to
be associated with a three times greater incidence of stroke
in the periprocedural period.28
Second, more than twice as many octogenarians had
contralateral internal carotid artery occlusion than nonoc-
togenarians, which one might expect to be associated with
greater risk. Although the OR of 0.32 associated with
contralateral occlusion was not significant (P  .28), it
unexpectedly suggested a protective effect. In previously
published work, contralateral occlusion had been consid-
ered a high-risk criterion.25 Ultimately, the effect of con-
tralateral occlusion has not been elucidated, occasionally
associated with a higher risk of periprocedural events in
some studies2,29 but not in others.30
One limitation of our study is the high number of
patients lost to follow-up. Only 173 (59%) of 295 nonoc-
togenarians and 39 (45%) of 87 octogenarians were avail-
able at 1 year. This was largely owing to failure to return, no
physician follow-up, or both. This, however, should not
affect the early 30-days results and should only decrease the
confidence in our 1-year comparisons. By 2 years, 86% of
patients were lost to follow-up, and we do not report the
analysis of these patients.
Another issue may be raised over the long 8-year ac-
crual span of this study, during which many technical
advances in carotid stenting occurred. For instance, many
of the patients were stented without cerebral protection, a
technical development during the latter half of the study
period presumed to decrease stroke rates.31 Some, in fact,
suggest that octogenarians may derive greater benefit in
terms of freedom from stroke with use of cerebral protec-
tion,19,32 potentially accounting for the higher stroke rates
seen in early studies of octogenarians.
This should not influence our results, however, as
worse outcomes in the octogenarian group were noted
despite a higher utilization of cerebral protection in that
group. Our current standard of care is to uniformly use
cerebral protection, when feasible, to prevent distal embo-
lization.33-38 This has become our routine since 2000 and
is consistent with others performing carotid artery stenting.
Of course, randomized clinical data are necessary to
confirm our findings and to determine the appropriateness
of carotid artery stenting in octogenarians. Caution should
be the rule in stenting octogenarians, however, especially in
asymptomatic patients, as both their short- and long-term
outcomes do not appear to be very encouraging. Ulti-
mately, determining the proper population to benefit from
carotid stenting is paramount as technology emerges and
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Dr Byung-Boon Lee (Reston, Va). I congratulate you for
such unique data that you shared with us. I enjoyed them enor-
mously but with some concern. Have you ever considered the
combined intracranial, either intracerebral or intracerebellar, vas-
cular lesion as a potential risk factor for this octogenarian group in
particular?
Dr Luke K. Marone. We do not have the data on the
percentage of intracranial or intracerebral lesions exhibited by each
cohort.
Dr Lee. My concern is the unclear role and significance of
intracranial lesions among the carotid surgery candidates in Korea.
We confirmed a higher incidence and prevalence of intracranial
lesions among carotid candidates in Korea through angiographic
assessment. Four-vessel angiostudy done to 235 Korean patients
with extracranial carotid disease showed 33.5% anatomically signif-
icant and also 11.2% hemodynamically significant intracranial,
either as cerebral and/or cerebellar lesions as incidental findings.
Hemodynamically significant lesions seem to affect the clinical
outcome with increasing morbidity and mortality in our series.
Putting this data together, I began to wonder how much this
incidentally found intracranial lesion, which is combined with
extracranial carotid lesion, would affect overall outcome of the
carotid surgery among ever-increasing octogenarians, especially
among the Asian population. I wish somebody would give a serious
look to this fact, especially among the candidates of endovascular
management.
As Dr Parodi showed yesterday, we still have a significant risk
of intracranial complication during the angioplasty and stent pro-
cedure, and we do not have a foolproof brain protection device.
The more we committed to this new therapy without knowingsuch unknown territory like multiple intracranial lesions. We really
have to take a second look at this issue in new era of endovascular
treatment as we did for the endarterectomy, before we somehow
wind up having trouble such as negligence. We used to joke that
unless you go to Chinatown to get Chinese women, you don’t
have to worry about the tandem lesion. But this is worse than a
tandem lesion, and Asians are coming. You would be better off to
know that these often multiple combined intracranial lesions are
more prevalent than you hope. So, I really would like to bring this
issue to your attention.
Dr Marone. Thank you.
Dr Robert Hobson (Newark, NJ). This certainly confirms
the impressions of the CREST investigators presented in the
Anaheim meeting and contradicts the impression that the octoge-
narian would somehow be an automatic candidate for carotid
artery stenting. And I think your conclusion should emphasize that
stenting in the higher-risk patient is the patient that has the greater
risk of stroke and death. We still don’t know what is going on in
conventional risk patients. And that is why in the randomized
phase of CREST, we are still randomizing good risk octogenarian
patients. But this stimulates my question. From your multivariate
analysis, it is still unclear to me what you think is going on with
these octogenarians. In CREST, we found that anatomical tortu-
osity of the cervical carotid artery was important. These patients
had a little bit more hemodynamic instability in the cardiac cath lab
while we were doing the procedures. Maybe the octogenarians just
don’t tolerate that as well. I’d be interested in your comments,
even though your multivariate analysis didn’t point out a great
many risks factors, what you think is going on with the octogenar-
ian in the high-risk group that makes them such a high risk for this
procedure.
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models. In each model, age always washed out as a significant
predictor of adverse event despite how we formulated the models.
We did not find any significant difference in how the octogenarians
fared during the procedure from a vasopressor requirement or in
the development of intraprocedural arrhythmias requiring therapy,
so I am not sure if those applied to this patient cohort, or if those
confounding variables applied. I actually did not run them because
they were not significant in the multivariate models and they did
not trend toward significance at all.
Dr M. Ashraf Mansour (Grand Rapids, Mich). You report 7
strokes in the younger group and 8 in the older group. Did you
review the stroke patients and see if all of them had embolic
protection devices or not? If an embolic protection device was
used, was there a problem retrieving the filter?Was there a problem
deploying the stent? Were more stents used in those older patients?
Dr Marone. In looking at those stroke patients in particular,
there was no significant difference in their utilization of protection
devices at all.
Dr Christopher Kwolek (Boston, Mass). It has been our
experience that in this elderly population there does seem to be a
higher incidence of extreme calcification, tortuosity, and this more
difficult arch anatomy. We also know that there is a learning curve
with carotid angioplasty and stenting. Perhaps that learning curve
is not just due to improving technical skills, but also in learning
which patients to back out on. Had you thought about going back
and quantitating the degree of tortuosity and disease in the arch
vessels and seeing if there was a relationship with strokes or poor
outcomes?
Dr Marone. We actually have not, as of yet, gone back and
reviewed the angiograms to assess for a particular tortuosity in the
octogenarians as opposed to the nonoctogenarian cohort. That
work could be done down the line.
Dr Richard Schutzer (Brooklyn, NY). I apologize if I missed
this, but was there any difference on the indications for the
procedure between the two groups?
Dr Marone. No, there was no difference in the symptom
status between the two groups.
Dr Takao Ohki (Bronx, NY). I want to challenge your
conclusion in which you said a randomized trial is needed. We
already have the Rubin series, the CREST series, and your series, allof which showed a three- to fourfold increase in neurological
complication in octogenarians. If you do a meta-analysis, I believe
that you would have a very powerful suggestion that octogenarians
do not do well following stenting. Do you really think it is ethical
to randomize octogenarians in the presence of such convincing
data?
Dr Marone. I think that is a very good comment, and I think
you are right. It would be probably impossible, based on all these
data that are accumulating, to randomize asymptomatic patients.
However, I think the symptomatic octogenarian may be a different
story and we may be able to put together a trial randomizing
symptomatic octogenarians.
Dr Enrico Ascher (Brooklyn, NY). This group of patients
between 75 and 80 years old, I am a little bit concerned about this
subgroup, because already in the septuagenarians you have got an
over 3% stroke rate. And most of your patients were asymptomatic.
Do you think that if you analyze a subset of patients between 75
and 80, would there be a little bit higher stroke rate that would
prohibit you from doing angioplasties in these patients, particularly
if they are asymptomatic?
Dr Marone. We actually have not done that entire subgroup
analysis. The analysis you saw was a trend analysis, which revealed
a trend of increasing rate with advancing age. But that analysis
could be done in the future.
Dr Ascher. It should be done.
Dr Juan Parodi (St. Louis, Mo). We have done cerebral
functional research studies in patients undergoing carotid artery
stenting, and we used transcranial Doppler routinely; what we
found is that older patients have in general a very poor cerebral
functional reserve, and using transcranial Doppler we detected
showers of particles in every single patient either using no protec-
tion or filters. Our hypothesis is that patients with low cerebral
vascular reserve have less tolerance to the challenge of cerebral
emboli. Using flow reversal as a method for cerebral protection
prevents emboli effectively, and in our initial 200 patients inci-
dence of stroke in patients older than 80 (36 patients) was nil. My
question: Have you done any cerebral functional studies or have
you used transcranial Doppler in these patients?
Dr Marone. As of yet we have not used transcranial Doppler
to evaluate for intracerebral emboli during the procedures.
